HC Wainwright Has Weak Outlook for Gossamer Bio Q1 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings estimates for shares of Gossamer Bio in a note issued to investors on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Separately, Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Trading Down 0.7 %

GOSS opened at $1.35 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55. The business’s 50 day moving average is $1.16 and its two-hundred day moving average is $0.98. The firm has a market cap of $306.75 million, a price-to-earnings ratio of -4.22 and a beta of 1.86.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors have recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP lifted its position in Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock worth $16,599,000 after acquiring an additional 9,162,117 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after purchasing an additional 3,041,058 shares during the last quarter. Silverarc Capital Management LLC grew its position in Gossamer Bio by 9.3% in the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after buying an additional 526,495 shares during the last quarter. Monaco Asset Management SAM grew its position in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after buying an additional 1,520,721 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock valued at $3,244,000 after buying an additional 457,179 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.